| 索引号 | JGXX-2025-10112 主题分类 监管信息 / 监督抽检信息 | | --- | --- | | 标题 | 国家药监局关于28批次不符合规定药品的通告 (2025年第30号) | | 发布日期 | 2025-08-27 | 经江苏省药品监督检验研究院等12家药品检验机构检验，共17家企业生产的28批次药品不符合规定。现将相关情况通告如下： 一、经江苏省药品监督检验研究院检验，标示为澳美制药厂生产的5批次夫西地酸乳膏不符合规定，不符合规定项目为粒度。 转自：国家药监局网站 九、经安徽省食品药品检验研究院检验，标示为四川金可药业有限责任公司、四川益祥康药业有限公司生产的2批次赤芍不符合规定，不符合规定项目为性 状。 十、经湖南省药品检验检测研究院检验，标示为安国市安兴中药饮片有限公司、河北康盛华药业有限公司、河北悦康志德药业有限公司生产的3批次红参 （红参片）不符合规定，不符合规定项目为鉴别；标示为辽宁龙参健康药业有限公司生产的1批次红参（红参片）不符合规定，不符合规定项目为其他有机 氯类农药残留量、总还原糖。 十一、经浙江省食品药品检验研究院检验，标示为江苏和生堂药业有限公司生产的1批次 ...

中新网8月27日电 国家药监局27日在官网发布关于28批次不符合规定药品的通告。经江苏省药品监督检 验研究院等12家药品检验机构检验，共17家企业生产的28批次药品不符合规定。 一、经江苏省药品监督检验研究院检验，标示为澳美制药厂生产的5批次夫西地酸乳膏不符合规定，不 符合规定项目为粒度。 二、经吉林省药品检验研究院检验，标示为万特制药(海南)有限公司生产的2批次氯雷他定糖浆不符合 规定，不符合规定项目为有关物质。 三、经天津市药品检验研究院检验，标示为上海海虹实业(集团)巢湖今辰药业有限公司生产的1批次磷 酸钠盐口服溶液不符合规定，不符合规定项目为相对密度。 四、经黑龙江省药品检验研究院检验，标示为陕西西岳制药有限公司生产的2批次托西酸舒他西林胶囊 不符合规定，不符合规定项目为溶出度。 五、经无锡市药品安全检验检测中心检验，标示为浙江金华康恩贝生物制药有限公司生产的1批次乙酰 半胱氨酸泡腾片不符合规定，不符合规定项目为性状。 六、经西藏自治区食品药品检验研究院检验，标示为西藏神猴药业有限责任公司生产的2批次二十五味 珊瑚丸不符合规定，不符合规定项目为重量差异。 七、经黑龙江省药品检验研究院检验，标示为湖北民 ...

央视网消息：国家药监局发布关于28批次不符合规定药品的通告（2025年第30号），详情如下： 四、经黑龙江省药品检验研究院检验，标示为陕西西岳制药有限公司生产的2批次托西酸舒他西林 胶囊不符合规定，不符合规定项目为溶出度。 五、经无锡市药品安全检验检测中心检验，标示为浙江金华康恩贝生物制药有限公司生产的1批次 乙酰半胱氨酸泡腾片不符合规定，不符合规定项目为性状。 六、经西藏自治区食品药品检验研究院检验，标示为西藏神猴药业有限责任公司生产的2批次二十 五味珊瑚丸不符合规定，不符合规定项目为重量差异。 七、经黑龙江省药品检验研究院检验，标示为湖北民康制药有限公司生产的2批次七厘散不符合规 定，不符合规定项目为含量测定。 八、经四川省药品检验研究院检验，标示为湖北瑞华制药有限责任公司生产的4批次清气化痰丸不 符合规定，不符合规定项目为装量差异。 九、经安徽省食品药品检验研究院检验，标示为四川金可药业有限责任公司、四川益祥康药业有限 公司生产的2批次赤芍不符合规定，不符合规定项目为性状。 十、经湖南省药品检验检测研究院检验，标示为安国市安兴中药饮片有限公司、河北康盛华药业有 限公司、河北悦康志德药业有限公司生产的3批 ...

国家药监局今天发布通告，经江苏省药品监督检验研究院等12家药品检验机构检验，共17家企业生产的 28批次药品不符合规定。 一、经江苏省药品监督检验研究院检验，标示为澳美制药厂生产的5批次夫西地酸乳膏不符合规定，不 符合规定项目为粒度。 二、经吉林省药品检验研究院检验，标示为万特制药（海南）有限公司生产的2批次氯雷他定糖浆不符 合规定，不符合规定项目为有关物质。 三、经天津市药品检验研究院检验，标示为上海海虹实业（集团）巢湖今辰药业有限公司生产的1批次 磷酸钠盐口服溶液不符合规定，不符合规定项目为相对密度。 四、经黑龙江省药品检验研究院检验，标示为陕西西岳制药有限公司生产的2批次托西酸舒他西林胶囊 不符合规定，不符合规定项目为溶出度。 五、经无锡市药品安全检验检测中心检验，标示为浙江金华康恩贝生物制药有限公司生产的1批次乙酰 半胱氨酸泡腾片不符合规定，不符合规定项目为性状。 六、经西藏自治区食品药品检验研究院检验，标示为西藏神猴药业有限责任公司生产的2批次二十五味 珊瑚丸不符合规定，不符合规定项目为重量差异。 七、经黑龙江省药品检验研究院检验，标示为湖北民康制药有限公司生产的2批次七厘散不符合规定， 不符合规定 ...

证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20250826 | □ 投资者关系活动 | 特定对象调研 □ 分析师会议 | | | --- | --- | --- | | □ | 媒体采访 业绩说明会  | | | 类别 □ | 新闻发布会 □ 路演活动 | | | □ | 现场参观 其他 □ | | | 参与单位名称及 | 通过全景网"投资者关系互动平台"（网址：http://ir.p5w.net） | | | 人员姓名 | 参与公司 年半年度业绩网上说明会的投资者 2025 | | | 时间 | 年 8 月 26 日（周二）下午 15:00~17:00 | 2025 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 1、董事、总经理张海安 | | | 上市公司接待人 | 2、董事会秘书胡菁菁 | | | 员姓名 | 3、财务总监王剑 | | | | 4、独立董事刘忠海 1、董秘您好，看到上半年华邦的业绩是超出预期的，希望下半 | | | | 年能继续保持。请问公司战略有没有变化？ | | | | 投 ...

Group 1 - China State Construction won multiple major projects with a total amount of 21.53 billion yuan, accounting for 1.0% of the audited revenue for 2024 [1] - Zhongtai Chemical's subsidiary has fully launched a methanol upgrading demonstration project, which will further reduce production costs [1] - Wide Special Materials expects a net profit increase of approximately 367.51% year-on-year for the first half of 2025, driven by improved demand and internal optimization [1][2] Group 2 - Longdi Group plans to exercise its preferential subscription rights to participate in the convertible bond issuance of its associate company, Yongqi Electronics, with an investment of no more than 89.249 million yuan [3] - Dayou Energy's subsidiary Mengjin Coal Mine has resumed production after a 38-day suspension due to an accident, with an annual capacity of 1.2 million tons [5] - Shanying International plans to repurchase shares worth between 500 million and 1 billion yuan, with a maximum repurchase price of 2.50 yuan per share [7] Group 3 - Huatai Securities has been approved to issue up to 10 billion yuan in technology innovation bonds to support investment in the technology innovation sector [9] - Weixin Kang's cooperative product, an injectable multivitamin, has passed the consistency evaluation, enhancing its market potential [10] - Jinpu Titanium's controlling shareholder will have 35 million shares auctioned, accounting for 3.55% of the company's total share capital [11] Group 4 - China Pharmaceutical plans to waive its preferential purchase rights for a 24% stake in Chongqing Medical Health Industry Co., with a base transfer price of 2.206 billion yuan [12] - Beijia Clean plans to reduce its shareholding by 1.99% due to funding needs [13] - Anpelon has obtained a design patent for a brake sensor, enhancing its technological capabilities [14] Group 5 - Zhongyue Holdings' subsidiary has received approval for a clinical trial application for a new drug, indicating progress in its pharmaceutical development [14] - Lijun Group's YJH-012 injection has been approved for clinical trials, showcasing its potential in treating gout [16] - Yageer has sold financial assets totaling 4.176 billion yuan, representing 10.13% of its audited net assets for 2024 [15] Group 6 - Tailing Micro expects a net profit increase of approximately 267% year-on-year for the first half of 2025, driven by customer demand and product sales [19] - Baotai plans to invest 287 million yuan to acquire a 51% stake in Shaanxi Wanhao Titanium Technology Co., enhancing its production capabilities [21] - Laime Pharmaceutical has received a drug registration certificate for azithromycin granules, expanding its product portfolio [23] Group 7 - KQ Bio has received approval for a new veterinary vaccine, marking a significant advancement in its product offerings [25] - Robotech signed a contract worth approximately 17.1 million euros, representing over 12.82% of its audited revenue for 2024 [26] - Alloy Investment is planning a control change, leading to a temporary suspension of its stock [27] Group 8 - Huabang Health's subsidiary has received approval for two dermatological drugs, indicating growth in its pharmaceutical pipeline [28] - Lingxiao Pump Industry plans to invest 60 million yuan in wealth management products, optimizing its financial strategy [29] - Jinzhong Technology has won projects totaling 113 million yuan, accounting for 6.39% of its expected revenue for 2024 [31] Group 9 - Yifan Pharmaceutical's subsidiary has received approval for a clinical trial of a growth hormone injection, indicating progress in its research and development [32] - Guiguan Electric plans to invest 395 million yuan in a photovoltaic project, reflecting its commitment to renewable energy [33] - Rili Technology intends to repurchase shares worth between 10 million and 20 million yuan, supporting its stock performance [34] Group 10 - Xingye Securities' chairman has resigned, leading to a change in leadership [35] - Jinko Solar has achieved third-party certification for its high-efficiency solar cells, setting a new industry record [37] - Changan Automobile's controlling shareholder has changed its name, reflecting a rebranding effort [38]

Group 1: Company Overview and Investment Activities - The company is Hangzhou Baicheng Pharmaceutical Technology Co., Ltd., with stock code 301096 and abbreviation Baicheng Pharmaceutical [1] - The investor relations activities include online meetings and strategy sessions held from June 9 to June 20, 2025 [2] - Key participants include the Chairman and General Manager, Lou Jinfang, and the Financial Director and Board Secretary, Cheng Dandan [2] Group 2: Drug Development Progress - The company has multiple new drug pipelines, with 2 IND approvals for Class 1 new drugs targeting areas such as the nervous system and oncology [3] - The global market for central nervous system drugs exceeded $500 billion in 2023, with China's market at approximately ¥173.4 billion, indicating significant growth potential [3] - The central nervous system drug market in China is projected to grow from about ¥40 billion in 2025 to ¥200 billion by 2030 [3] Group 3: Specific Drug Projects - BIOS-0623 is a novel pain relief drug with advantages such as rapid onset and lower effective doses, showing superior efficacy compared to pregabalin [4] - BIOS-0632 is a strong AAK1 kinase inhibitor that demonstrates faster onset and better efficacy in diabetic neuropathic pain models compared to existing treatments [4] - BIOS-0629, a potential Best-in-Class second-generation XPO1 inhibitor, shows significant anti-tumor efficacy in various cancer models [5][6] Group 4: Market Trends and Opportunities - The global market for anti-tumor drugs reached $235.7 billion in 2023, with China's market at approximately ¥280 billion, driven by increasing cancer incidence [5] - The autoimmune disease drug market is expected to grow from $113.7 billion in 2018 to $176.7 billion by 2030, with a CAGR of 3.7% globally and over 20% in China [6][7] Group 5: Improved Drug Development - The company has over 20 projects in the improved drug category, with 11 receiving clinical approval, indicating a robust pipeline [10] - The market for improved drugs in China is expected to reach ¥560 billion by 2025, suggesting a favorable investment return [11][12] Group 6: Subsidiary Development - The subsidiary, Saimer Pharmaceutical, aims to become a global supplier of raw materials and formulations, with a production area of over 260 acres and 16.3 million square meters of GMP-compliant facilities [13][14] - Saimer has successfully registered 435 projects and has 49 products approved, showcasing its strong production capabilities [14] Group 7: CRO Business Status - The CRO/CDMO industry is experiencing a downturn due to cautious investment and increased competition, leading to a decline in orders [15][16] - Recent regulatory changes are expected to positively impact the CRO/CDMO sector, potentially restoring investment enthusiasm [16][17] Group 8: International Expansion Plans - The company is accelerating its internationalization efforts, establishing partnerships to enhance global resource connectivity [19] - Saimer has obtained the EU CEP certificate for minoxidil, marking a significant step in international business expansion [19]